Details
Stereochemistry | RACEMIC |
Molecular Formula | C13H16N2.ClH |
Molecular Weight | 236.74 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.C1CN=C(N1)C2CCCC3=C2C=CC=C3
InChI
InChIKey=BJORNXNYWNIWEY-UHFFFAOYSA-N
InChI=1S/C13H16N2.ClH/c1-2-6-11-10(4-1)5-3-7-12(11)13-14-8-9-15-13;/h1-2,4,6,12H,3,5,7-9H2,(H,14,15);1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C13H16N2 |
Molecular Weight | 200.2795 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095203 Sources: www.ncbi.nlm.nih.gov/pubmed/18259967 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | TYZINE Approved UseTyzine Nasal Solution is indicated for decongestion of nasal and nasopharyngeal mucosa. Launch Date1979 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.218 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21972870/ |
2 drop 4 times / day multiple, ocular dose: 2 drop route of administration: Ocular experiment type: MULTIPLE co-administered: |
TETRAHYDROZOLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.46 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21972870/ |
2 drop 4 times / day multiple, ocular dose: 2 drop route of administration: Ocular experiment type: MULTIPLE co-administered: |
TETRAHYDROZOLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21972870/ |
2 drop 4 times / day multiple, ocular dose: 2 drop route of administration: Ocular experiment type: MULTIPLE co-administered: |
TETRAHYDROZOLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
7500 ug single, oral Overdose |
healthy, 16 years n = 1 Health Status: healthy Age Group: 16 years Sex: M Population Size: 1 Sources: |
Other AEs: Sinoatrial node dysfunction... |
0.3 mg/kg single, oral Overdose Dose: 0.3 mg/kg Route: oral Route: single Dose: 0.3 mg/kg Sources: |
healthy, 20 months-2 years n = 2 Health Status: healthy Age Group: 20 months-2 years Sex: M+F Population Size: 2 Sources: |
Other AEs: Bradycardia, Hypertension... Other AEs: Bradycardia (2 patients) Sources: Hypertension (1 patient) Gasping (2 patients) |
250 ug 3 times / day multiple, oral Overdose Dose: 250 ug, 3 times / day Route: oral Route: multiple Dose: 250 ug, 3 times / day Sources: |
unhealthy, 25 days n = 1 Health Status: unhealthy Age Group: 25 days Sex: M Population Size: 1 Sources: |
Other AEs: Hypotonia... |
250 ug 3 times / day multiple, oral Overdose Dose: 250 ug, 3 times / day Route: oral Route: multiple Dose: 250 ug, 3 times / day Sources: |
unhealthy, 25 days n = 1 Health Status: unhealthy Condition: mild fever Age Group: 25 days Sex: M Population Size: 1 Sources: |
Other AEs: Apnea... |
15000 ug single, oral Overdose Dose: 15000 ug Route: oral Route: single Dose: 15000 ug Sources: |
healthy, 41 years n = 1 Health Status: healthy Age Group: 41 years Sex: M Population Size: 1 Sources: |
Other AEs: Hypothermia, Bradycardia... Other AEs: Hypothermia (1 patient) Sources: Bradycardia (1 patient) Hypotension (1 patient) Miosis (1 patient) Lethargy (1 patient) Mucous membrane disorder (NOS) (1 patient) Bowel sounds decreased (1 patient) Chest pain (1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Sinoatrial node dysfunction | 1 patient | 7500 ug single, oral Overdose |
healthy, 16 years n = 1 Health Status: healthy Age Group: 16 years Sex: M Population Size: 1 Sources: |
Hypertension | 1 patient | 0.3 mg/kg single, oral Overdose Dose: 0.3 mg/kg Route: oral Route: single Dose: 0.3 mg/kg Sources: |
healthy, 20 months-2 years n = 2 Health Status: healthy Age Group: 20 months-2 years Sex: M+F Population Size: 2 Sources: |
Bradycardia | 2 patients | 0.3 mg/kg single, oral Overdose Dose: 0.3 mg/kg Route: oral Route: single Dose: 0.3 mg/kg Sources: |
healthy, 20 months-2 years n = 2 Health Status: healthy Age Group: 20 months-2 years Sex: M+F Population Size: 2 Sources: |
Gasping | 2 patients | 0.3 mg/kg single, oral Overdose Dose: 0.3 mg/kg Route: oral Route: single Dose: 0.3 mg/kg Sources: |
healthy, 20 months-2 years n = 2 Health Status: healthy Age Group: 20 months-2 years Sex: M+F Population Size: 2 Sources: |
Hypotonia | 1 patient | 250 ug 3 times / day multiple, oral Overdose Dose: 250 ug, 3 times / day Route: oral Route: multiple Dose: 250 ug, 3 times / day Sources: |
unhealthy, 25 days n = 1 Health Status: unhealthy Age Group: 25 days Sex: M Population Size: 1 Sources: |
Apnea | 1 patient | 250 ug 3 times / day multiple, oral Overdose Dose: 250 ug, 3 times / day Route: oral Route: multiple Dose: 250 ug, 3 times / day Sources: |
unhealthy, 25 days n = 1 Health Status: unhealthy Condition: mild fever Age Group: 25 days Sex: M Population Size: 1 Sources: |
Bowel sounds decreased | 1 patient | 15000 ug single, oral Overdose Dose: 15000 ug Route: oral Route: single Dose: 15000 ug Sources: |
healthy, 41 years n = 1 Health Status: healthy Age Group: 41 years Sex: M Population Size: 1 Sources: |
Bradycardia | 1 patient | 15000 ug single, oral Overdose Dose: 15000 ug Route: oral Route: single Dose: 15000 ug Sources: |
healthy, 41 years n = 1 Health Status: healthy Age Group: 41 years Sex: M Population Size: 1 Sources: |
Chest pain | 1 patient | 15000 ug single, oral Overdose Dose: 15000 ug Route: oral Route: single Dose: 15000 ug Sources: |
healthy, 41 years n = 1 Health Status: healthy Age Group: 41 years Sex: M Population Size: 1 Sources: |
Hypotension | 1 patient | 15000 ug single, oral Overdose Dose: 15000 ug Route: oral Route: single Dose: 15000 ug Sources: |
healthy, 41 years n = 1 Health Status: healthy Age Group: 41 years Sex: M Population Size: 1 Sources: |
Hypothermia | 1 patient | 15000 ug single, oral Overdose Dose: 15000 ug Route: oral Route: single Dose: 15000 ug Sources: |
healthy, 41 years n = 1 Health Status: healthy Age Group: 41 years Sex: M Population Size: 1 Sources: |
Lethargy | 1 patient | 15000 ug single, oral Overdose Dose: 15000 ug Route: oral Route: single Dose: 15000 ug Sources: |
healthy, 41 years n = 1 Health Status: healthy Age Group: 41 years Sex: M Population Size: 1 Sources: |
Miosis | 1 patient | 15000 ug single, oral Overdose Dose: 15000 ug Route: oral Route: single Dose: 15000 ug Sources: |
healthy, 41 years n = 1 Health Status: healthy Age Group: 41 years Sex: M Population Size: 1 Sources: |
Mucous membrane disorder (NOS) | 1 patient | 15000 ug single, oral Overdose Dose: 15000 ug Route: oral Route: single Dose: 15000 ug Sources: |
healthy, 41 years n = 1 Health Status: healthy Age Group: 41 years Sex: M Population Size: 1 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Gingival tissue inflammatory response following treatment with chemical retraction agents in Beagle dogs. | 2001 |
|
Sinoatrial node arrest following tetrahydrozoline ingestion. | 2004 Oct |
|
Effects of two eye drop products on computer users with subjective ocular discomfort. | 2005 Jan |
|
Ophthalmic delivery systems based on drug-polymer-polymer ionic ternary interaction: in vitro and in vivo characterization. | 2006 Jan |
|
Development of a multicommutated flow system with chemiluminometric detection for quantification of gentamicin in pharmaceuticals. | 2010 |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
Sample Use Guides
Adults and Children 6 Years and Over, Tyzine 0.1% Nasal Solution: It is recommended that 2 to 4 drops be instilled in each nostril as needed, never more often than every three hours. Adults and Children 6 Years and Over, Tyzine 0.1% Nasal Spray: It is recommended to squeeze quickly and firmly three or four times the spray in each nostril as needed, never more often than every three hours. Children 2 to 6 Years of Age, Tyzine 0.05 % Pediatric Nasal Drops: It is recommended that 2 to 3 drops be instilled in each nostril as needed, and never more often than every three hours.
Route of Administration:
Nasal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6289955
Rat and rabbit aortae were treated with tetrahydrozoline at concentrations from 10(-7) to 10(-5) M to determine the drug relative efficacy. Emax value was 0.51 for the rabbit aortae and 0 for the rat aortae.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:00:45 GMT 2023
by
admin
on
Fri Dec 15 15:00:45 GMT 2023
|
Record UNII |
0YZT43HS7D
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 349.18
Created by
admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
|
||
|
NCI_THESAURUS |
C29709
Created by
admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
0YZT43HS7D
Created by
admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
|
PRIMARY | |||
|
SUB04765MIG
Created by
admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
|
PRIMARY | |||
|
100000092231
Created by
admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
|
PRIMARY | |||
|
9492
Created by
admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
|
PRIMARY | |||
|
57983
Created by
admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
|
PRIMARY | RxNorm | ||
|
CHEMBL1266
Created by
admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
|
PRIMARY | |||
|
m10634
Created by
admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
|
PRIMARY | Merck Index | ||
|
208-329-3
Created by
admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
|
PRIMARY | |||
|
1652001
Created by
admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
|
PRIMARY | |||
|
0YZT43HS7D
Created by
admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
|
PRIMARY | |||
|
DBSALT001254
Created by
admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
|
PRIMARY | |||
|
10648
Created by
admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
|
PRIMARY | |||
|
C47749
Created by
admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
|
PRIMARY | |||
|
C005810
Created by
admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
|
PRIMARY | |||
|
DTXSID7045316
Created by
admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
|
PRIMARY | |||
|
757339
Created by
admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
|
PRIMARY | |||
|
522-48-5
Created by
admin on Fri Dec 15 15:00:45 GMT 2023 , Edited by admin on Fri Dec 15 15:00:45 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
USP
|
||
|
PARENT -> SALT/SOLVATE | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
||
|
ENANTIOMER -> RACEMATE |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
Ph.Eur.; USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |